Isto Biologics, a provider of surgical-based, osteo-biologic regeneration technologies and cell-based therapies, has purchased TheraCell Inc., a California-based regenerative medicine company. Isto is a portfolio company of Thompson Street Capital Partners.
The deal will enhance Isto’s services for surgical and clinical care procedures across spine, orthopedics and sports medicine. TheraCell will expand Isto’s portfolio of orthopedic grafts will introducing its proprietary and patented TheraFuze DBF. Isto will integrate the patent technology into its Influx line.
“We are thrilled to add TheraCell’s unmatched technology to our market-leading biologics portfolio,” said Don Brown, CEO of Isto Biologics. “TheraCell has excelled in developing advanced bone integrating, anchoring, and bridging technologies for spinal repair for over a decade.”
“Both Isto Biologics and TheraCell have achieved success in developing and introducing innovative, first-of-their-kind product offerings to help patients heal faster,” said Harry Holiday, chairman of the board at Isto Biologics and managing director at TSCP. “Adding TheraCell’s product portfolio to Isto’s top-tier sales team will add tremendous value to TheraCell’s place in the market. We anticipate an unparalleled synergy by combining these two great organizations.”